Are AstraZeneca shares a growth buy for 2023?

AstraZeneca’s surging share price has made it the most valuable business in the FTSE 100. Roland Head analyses what’s next for the pharma giant.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

positive mental health woman

Image source: Getty Image

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

A strong share price performance can be a sign that a business is growing steadily. That seems to be true at AstraZeneca (LSE: AZN), which reported a 50% increase in earnings during the first nine months of this year.

The FTSE 100 pharmaceutical group’s stock has risen by more than 30% so far in 2022. As a result, AstraZeneca has overtaken Shell to become the most valuable company on the London Stock Exchange, with a market cap of £175bn.

AstraZeneca is a business I’d like to own, but I’m a little wary about buying at the current price. Is the company’s strong growth already priced into its shares, or is there more to come? Here’s what I think.

Delivering as planned

After years of heavy investment in new medicines, its efforts are starting to pay off.

Sales rose by 30% to $33.1bn during the first nine months of this year. According to management, growth came “from all disease areas”. This included a 24% increase in revenue from cancer treatments. There was also a contribution from Alexion, which AstraZeneca acquired in July.

Looking ahead, the pipeline seems strong for future sales growth.

The business has won 19 regulatory approvals for new products in major markets since its half-year results were published earlier this year.

Phase III clinical testing has also delivered positive results for breast cancer drugs danicopan and capivasertib, opening the way for potential commercialisation.

Overall, my feeling is that there will be plenty of opportunities for sales growth over the next few years.

What do the brokers say?

City analysts covering AstraZeneca seem optimistic about the outlook for the firm. They’re forecasting strong earnings growth between now and 2024:

YearForecast earnings per shareForecast P/E
2022$6.66 (+26%)20.6
2023$7.44 (+12%)18.5
2024$8.85 (+19%)15.5

These numbers suggest to me that the shares are not too expensive on a forward view.

However, one concern I have is that AstraZeneca’s earnings come with heavy adjustments. These exclude certain costs. If these are included, reported profits are much lower.

During the first nine months of this year the company reported statutory earnings of $1.54 per share, but adjusted earnings of $5.28 per share. That’s a huge difference. Which of these numbers should I use to value the stock?

In situations like this, my preference is to look at how much surplus cash the business is generating.

I’ve crunched the numbers and my sums suggest AstraZeneca generated underlying free cash flow of $3.60 per share during the first nine months of the year, excluding acquisition payments.

On this basis, I estimate that AstraZeneca shares are trading on about 28 times forecast free cash flow. That’s not obviously cheap.

My verdict

Overall, I think that this is a good business with attractive long-term growth prospects.

However, I prefer to take a conservative view on valuation and focus on cash generation. By this measure, these shares already look fairly priced to me.

If we see another market slump next year — or if the company’s performance disappoints investors — I think the share price could fall sharply.

But on balance, I think there will probably be better buying opportunities in 2023. I wouldn’t rush to buy right now.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Roland Head has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

The market is wrong about this FTSE 250 stock. I’m buying it in April

Stephen Wright thinks investors should look past a 49% decline in earnings per share and consider investing in a FTSE…

Read more »

Black father and two young daughters dancing at home
Investing Articles

1 FTSE 250 stock I own, and 1 I’d love to buy

Our writer explains why she’s eyeing up this FTSE 250 growth phenomenon, and may buy more shares in this property…

Read more »

View of Tower Bridge in Autumn
Investing Articles

The FTSE 100 is closing in on 8,000 points! Here’s what I’m buying before it’s too late!

As the FTSE 100 keeps gaining momentum, this Fool is on the lookout for bargains. Here's one stock he'd willingly…

Read more »

Investing Articles

3 ideas to help investors aim for a million-pound Stocks & Shares ISA

The UK has a growing number of Stocks and Shares ISA millionaires, and this plan may be one of the…

Read more »

Illustration of flames over a black background
Investing Articles

2 red-hot UK growth stocks to consider buying in April

These two growth stocks are performing well, but can they continue to deliver for investors through 2024 and beyond?

Read more »